In this preliminary study, with a small number of patients, we observed a difference in point estimate; however, a significant difference in LVEF decline between breast cancer patients living in metro and non-metro geographic locations was not reached 6 months after initiation of doxorubicin-based chemotherapy.

In this preliminary study, with a small number of patients, we observed a difference in point estimate; however, a significant difference in LVEF decline between breast cancer patients living in metro and non-metro geographic locations was not reached 6 months after initiation of doxorubicin-based chemotherapy. Future studies are needed with larger sample sizes to determine a significant difference in metro and non-metro LVEF decline.